SubscribeLogin
Published

FDA Approves Groundbreaking Heart Drug: Bridging New Frontiers

Summary by Devdiscourse
FDA Approves Groundbreaking Heart Drug: Bridging New Frontiers The U.S. Food and Drug Administration has announced its approval of BridgeBio's innovative drug, Attruby, aimed at treating transthyretin amyloid cardiomyopathy, a rare heart condition. BridgeBio's drug marks the first new entrant in a market that has long been dominated by Pfizer's Vyndaqel.Meanwhile, Merck's Winrevair has proven effective in reducing mortality in individuals with …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

United StatesUnited States
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal